Senores Pharma.

Which are the latest news on Senores Pharma.?

Why is Senores Pharmaceuticals Ltd falling/rising?

As of 05-Sep, Senores Pharmaceuticals Ltd's stock is experiencing a decline of -5.35 (-0.37%) and has fallen for three consecutive days, totaling a drop of -1.68%. Despite strong long-term growth and increased institutional investment, short-term indicators show weakness and decreased investor participation.

As of 05-Sep, Senores Pharmaceuticals Ltd's stock price is currently falling, with a change of -5.35 (-0.37%). This decline is part of a broader trend, as the stock has been losing for the last three days, resulting in a total drop of -1.68% during this period. Additionally, the stock's performance today is described as inline with the sector, indicating that it is not outperforming its peers.<BR><BR>Investor participation has also decreased, evidenced by a significant drop in delivery volume, which fell by -63.96% compared to the 5-day average. This reduction in trading activity may reflect waning interest among investors. While the stock remains above its 50-day, 100-day, and 200-day moving averages, it is below its 5-day and 20-day moving averages, suggesting short-term weakness.<BR><BR>Despite these negative indicators, the company has shown strong long-term growth, with net sales increasing at an annual rate of 71.70% and operating profit rising by 108.34%. Furthermore, institutional investors have increased their stake in the company, which could provide some support for the stock in the long run. However, the immediate price movement reflects a combination of recent losses and declining investor engagement.

Should I buy, sell or hold Senores Pharmaceuticals Ltd?

What does Senores Pharma. do?

Senores Pharmaceuticals Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, recently converted to a public limited company in September 2023, with net sales of 180 Cr and a net profit of 31 Cr reported for June 2026. The company has a market cap of INR 6,766 Cr and key metrics include a P/E of 53.00 and a debt-equity ratio of 0.20.

Overview:<BR>Senores Pharmaceuticals Ltd is a small-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>The company was originally incorporated as "Senores Pharmaceuticals Private Limited" in 2017 and later converted to a public limited company, changing its name to "Senores Pharmaceuticals Limited" in September 2023. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 180 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 31 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 6,766 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 53.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.20<BR>- Return on Equity: 12.36%<BR>- Price to Book: 7.33<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Senores Pharma.?

Senores Pharma's peers include Sanofi Consumer, P & G Health Ltd, Strides Pharma, Aarti Pharma, Sanofi India, Bliss GVS Pharma, SPARC, Supriya Lifesci., Innova Captab, and IOL Chemicals. Senores Pharma shows excellent growth and a good capital structure, with a 1-year return of 107.85%, while Bliss GVS Pharma leads with a 295.64% return.

Peers: The peers of Senores Pharma are Sanofi Consumer, P & G Health Ltd, Strides Pharma, Aarti Pharma, Sanofi India, Bliss GVS Pharma, SPARC, Supriya Lifesci., Innova Captab, and IOL Chemicals.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi Consumer, P & G Health Ltd, and Sanofi India, while Average management risk is found at Strides Pharma, Aarti Pharma, Senores Pharma., Bliss GVS Pharma, SPARC, and IOL Chemicals, and Good management risk is noted at Supriya Lifesci. and Innova Captab. Growth is Excellent at Senores Pharma. and SPARC, while Good growth is seen at Strides Pharma and Average growth is found at Innova Captab. Below Average growth is noted at Sanofi Consumer, P & G Health Ltd, Aarti Pharma, Sanofi India, Bliss GVS Pharma, Supriya Lifesci., and IOL Chemicals. Capital Structure is Excellent at Sanofi Consumer, P & G Health Ltd, Aarti Pharma, Bliss GVS Pharma, Supriya Lifesci., and Innova Captab, while Good capital structure is seen at Senores Pharma. and Average at SPARC.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bliss GVS Pharma at 295.64%, while the lowest is Sanofi India at -39.16%. Senores Pharma.'s 1-year return of 107.85% is significantly higher than that of Sanofi India but lower than that of Bliss GVS Pharma. Additionally, Sanofi India and IOL Chemicals have negative six-month returns.

How big is Senores Pharma.?

As of 31st August, Senores Pharmaceuticals Ltd has a market capitalization of 6,766.00 Cr, with recent net sales of 688.11 Cr and a net profit of 126.37 Cr. The latest balance sheet shows shareholder's funds of 786.18 Cr and total assets of 1,208.19 Cr.

As of 31st August, Senores Pharmaceuticals Ltd has a market capitalization of 6,766.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Senores Pharmaceuticals reported Net Sales of 688.11 Cr and a Net Profit of 126.37 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 786.18 Cr and Total Assets of 1,208.19 Cr.

Are Senores Pharmaceuticals Ltd latest results good or bad?

Senores Pharmaceuticals Ltd's latest results show strong year-on-year revenue growth of 30.60% and a net profit increase of 55.70%, but there was a sequential profit decline of 2.82% and rising costs, indicating mixed performance overall. Investors should consider both the positive revenue trends and the challenges ahead.

Senores Pharmaceuticals Ltd's latest results present a mixed picture. On the positive side, the company achieved a net profit of ₹30.72 crores for Q1 FY27, which is a significant increase of 55.70% year-on-year. Additionally, revenue grew by 30.60% compared to the same quarter last year, reaching ₹180.21 crores, marking the highest quarterly sales on record for the company.<BR><BR>The operating margin also showed improvement, rising to 29.83%, which is an increase of 269 basis points from the previous quarter. This indicates better operational efficiency and cost management.<BR><BR>However, there are some challenges to consider. The net profit saw a sequential decline of 2.82% compared to the previous quarter, which raises concerns about profitability despite the strong revenue growth. The company is also facing elevated interest costs and a significant drop in other income, which contributed to the decline in overall profitability.<BR><BR>Overall, while the revenue growth and operational improvements are commendable, the sequential profit decline and rising costs suggest that the company is navigating some headwinds. Investors may want to weigh these factors carefully when assessing the company's performance.

When is the next results date for Senores Pharmaceuticals Ltd?

The next results date for Senores Pharmaceuticals Ltd is July 27, 2026.

The next results date for Senores Pharmaceuticals Ltd is scheduled for July 27, 2026.

How has been the historical performance of Senores Pharma.?

Senores Pharma experienced significant growth from March 2024 to March 2025, with net sales rising from 214.52 Cr to 398.25 Cr and profit after tax increasing from 32.71 Cr to 58.34 Cr, despite higher raw material and employee costs. Total assets and liabilities both grew to 1,208.19 Cr, while cash flow from financing activities improved significantly.

Answer:<BR>The historical performance of Senores Pharma shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Senores Pharma's net sales increased substantially from 214.52 Cr in March 2024 to 398.25 Cr in March 2025, reflecting strong operational growth. Total operating income followed the same trend, rising to 398.25 Cr from 214.52 Cr. However, raw material costs surged to 91.64 Cr from 31.96 Cr, and employee costs also rose to 60.37 Cr from 35.46 Cr, contributing to a total expenditure of 308.55 Cr, up from 172.92 Cr. Operating profit (PBDIT) improved significantly to 108.96 Cr from 44.42 Cr, with profit before tax reaching 70.57 Cr compared to 24.95 Cr the previous year. Profit after tax also saw an increase to 58.34 Cr from 32.71 Cr. The company's total assets grew to 1,208.19 Cr from 606.92 Cr, while total liabilities increased to 1,208.19 Cr from 606.92 Cr as well. Cash flow from operating activities remained negative at -45.00 Cr, but cash flow from financing activities turned positive at 573.00 Cr, leading to a net cash inflow of 97.00 Cr, up from 7.00 Cr. Overall, Senores Pharma demonstrated robust growth in revenue and profitability, alongside increased asset and liability levels.

Is Senores Pharma. overvalued or undervalued?

As of September 18, 2025, Senores Pharma is considered very expensive and overvalued with a PE ratio of 56.49 and lower returns compared to peers, despite a year-to-date stock performance of 25.84% against the Sensex's 6.24%.

As of 18 September 2025, the valuation grade for Senores Pharma has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued, with a PE ratio of 56.49, an EV to EBIT of 44.43, and an EV to EBITDA of 36.09. These ratios are considerably higher than its peers, such as Sun Pharma, which has a PE ratio of 34.46 and an EV to EBITDA of 23.34, and Cipla, which boasts a more attractive PE ratio of 23.65 and an EV to EBITDA of 16.67.<BR><BR>In comparison to its industry, Senores Pharma's financial metrics suggest that it is not only overvalued but also lacks competitive returns, as evidenced by its ROE of 7.45% and ROCE of 10.18%. While the stock has outperformed the Sensex year-to-date with a return of 25.84% compared to the Sensex's 6.24%, the overall valuation metrics indicate that investors may be paying a premium that is not justified by the company's financial performance.

What is the technical trend for Senores Pharma.?

As of March 10, 2025, Senores Pharma's technical trend is neutral with no strong signals, as indicators like MACD and RSI show a sideways movement, despite recent outperformance against the Sensex.

As of 10 March 2025, the technical trend for Senores Pharma has changed to sideways. The current technical stance is neutral, with no strong bullish or bearish signals evident. The MACD, RSI, and other indicators do not provide clear directionality on the weekly or monthly time frames. The Dow Theory indicates no trend on the weekly and monthly levels, and the On-Balance Volume (OBV) also shows no trend. The stock's recent performance has outpaced the Sensex over the past week and month, but the year-to-date return is negative, suggesting mixed sentiment. Overall, the lack of definitive indicators keeps the outlook neutral.

Who are the top shareholders of the Senores Pharma.?

The top shareholders of Senores Pharma include promoter Swapnil Jatin Shah with 7.72%, Aditya Birla Sun Life Insurance Company Limited at 3.71%, mutual funds with 3.23%, foreign institutional investors holding 4.17%, and individual investors collectively owning 31.43%.

The top shareholders of Senores Pharma include the promoters, who are the majority shareholders. The promoter with the highest holding is Swapnil Jatin Shah, owning 7.72% of the company. Additionally, Aditya Birla Sun Life Insurance Company Limited is the highest public shareholder, holding 3.71%. The company also has mutual funds holding 3.23% across five schemes and foreign institutional investors (FIIs) holding 4.17% through 21 different entities. Individual investors collectively hold 31.43% of the shares.

Has Senores Pharma. declared dividend?

No Dividend History Available